Exosome-mediated delivery of inflammation-responsive II-10 mRNA for controlled atherosclerosis treatment

Te Bu¹#, Zhelong Li¹#, Ying Hou¹#, Wenqi Sun¹, Rongxin Zhang², Lianbi Zhao¹, Mengying Wei², Guodong Yang², Lijun Yuan¹★

¹. Department of Ultrasound Diagnostics, Tangdu Hospital, Fourth Military Medical University, Xi'an, People's Republic of China.
². The State Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, People's Republic of China.

#These authors contributed equally to this article.
★Corresponding author: Lijun Yuan, Department of Ultrasound Diagnostics, Tangdu Hospital, Fourth Military Medical University, Xinsi Road NO. 569th, 710038, Xi'an, China. E-mail: yuanlj@fmmu.edu.cn; Tel: +862984777471; Fax: +862984777471.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Abstract

Rationale: Tailored inflammation control is badly needed for the treatment of kinds of inflammatory diseases, such as atherosclerosis. IL-10 is a potent anti-inflammatory cytokine, while systemic and repeated delivery could cause detrimental side-effects due to immune repression. In this study, we have developed a nano-system to deliver inflammation-responsive II-10 mRNA preferentially into macrophages for tailored inflammation control.

Methods: II-10 was engineered to harbor a modified HCV-IRES (hepatitis C virus internal ribosome entry site), in which the two miR-122 recognition sites were replaced by two miR-155 recognition sites. The translational responsiveness of the engineered mRNA to miR-155 was tested by Western blot or ELISA. Moreover, the engineered II-10 mRNA was passively encapsulated into exosomes by forced expression in donor cells. Therapeutic effects on atherosclerosis and the systemic leaky expression effects in vivo of the functionalized exosomes were analyzed in ApoE-/- (Apolipoprotein E-deficient) mice.

Results: The engineered IRES-II-10 mRNA could be translationally activated in cells when miR-155 was forced expressed or in M1 polarized macrophages with endogenous miR-155 induced. In addition, the engineered IRES-II-10 mRNA, when encapsulated into the exosomes, could be efficiently delivered into macrophages and some other cell types in the plaque in ApoE-/-mice. In the recipient cells of the plaque, the encapsulated II-10 mRNA was functionally translated into protein, with relatively low leaky in other tissues/organs without obvious inflammation. Consistent with the robust II-10 induction in the plaque, exosome-based delivery of the engineered II-10 could alleviate the atherosclerosis in ApoE-/- mice.

Conclusion: Our study established a potent platform for controlled inflammation control via exosome-based systemic and repeated delivery of engineered II-10 mRNA, which could be a promising strategy for atherosclerosis treatment.

Key words: Atherosclerosis; exosomes; interleukin-10; inflammation-responsive; internal ribosome entry site

Introduction

Atherosclerosis (AS), the major cause of cardiovascular disease (CVD), is a chronic inflammatory condition characterized by plaque builds up in the walls of the arteries [1-3]. Currently, clinical treatments of atherosclerosis mainly include lifestyle interventions [4], lipid-lowering therapies [5] and anti-thrombotic treatments [6]. Accumulating evidence suggests that anti-inflammatory therapy opens a new window for atherosclerosis treatment [7]. For example, the therapeutic effects and safety of interleukin-1β inhibitor Canakinumab [8], lipase A2 inhibitor [9], and p38MAPK inhibitor Losmapimod [10] are investigated in clinical trial. Notably, these therapeutics mostly depend on frequently systemic
injection, with unexpected side-effects unavoidable. Thus, development of novel anti-inflammatory strategy with high delivery specificity, lower off-target effects is badly needed.

Exosomes are extracellular vesicles originating from endosome with a diameter of about 40-160 nm (an average of about 100 nm) and a density of 1.13-1.18 g/mL, carrying a variety of cargoes, such as proteins and nucleic acids, which can regulate pathological or physiological processes and participate in intercellular communication [11]. Exosomes are promising as drug delivery carriers because of the good stability in circulation and strong ability to cross a variety of biological barriers [11-13]. However, beyond the target tissues/cells, exosomes are taken up by many other cells throughout the body. Exosome tracking analysis has revealed that exosomes are inevitably endocytosed by liver, spleen, bone marrow and other organs enriched with mononuclear phagocyte system [14, 15]. In addition to the surface functionalization of exosomes, development of inflammation-responsive pro-drug holds as a feasible choice.

IL-10, is a soluble cytokine produced by macrophages, regulatory T cells and some other cell types. IL-10 plays a major role in limiting inflammation, preventing tissue damage. Therapeutic delivery of IL-10 has been shown to suppress atherosclerosis [16-19]. In this study, IL-10 mRNA was engineered to harbor a modified HCV-IRES (hepatitis C virus-internal ribosome entry site) responsive to miR-155. The engineered IL-10 mRNA could be efficiently delivered into macrophages in the plaque in ApoE-/- mice when encapsulated into the exosomes. Exosome-based delivery of the engineered IL-10 mRNA could alleviate the atherosclerosis in ApoE-/- mice while had minimal side-effects. Our study established a potent platform for tailored inflammation control via exosome-based systemic and repeated delivery of engineered IL-10 mRNA, which could be a promising strategy for atherosclerosis treatment.

Results

Engineering of inflammation-responsive IL-10 mRNA

It has been found that the IRES of HCV is responsible for the specific translation of viral proteins in liver as the high abundance of miR-122 there could change the conformation of the IRES [20, 21]. Replacement of the miR-122 recognition sites in the HCV-IRES to sequences recognized by other miRNAs make it possible to construct miRNA-responsive mRNA practical [22]. In order to construct an inflammation-responsive mRNA in the context of atherosclerosis, we first wanted to identify an inflammation-associated miRNA. Previous study [23] has confirmed that the content of miR-155 in plaques of patients with AS is significantly increased. Together, the data suggested that miR-155 might be chosen as the miRNA for construction of inflammation-responsive mRNA.

For construction of miR-155-activated IL-10 mRNA expression system, the IRES sequence of HCV recognized by miR-122 (Figure S1, denoted as S1 and S2) has been changed to the sequence complementary to miR-155 during the cloning of the expressing plasmid (Figure 1A). Upon transfection, the IRES-IL-10 transcript was synthesized by the cell (Figure S2). To explore the responsiveness of the designed IRES-IL-10 mRNA to miR-155, miR-155 mimics or negative control (NC) were co-transfected into HEK293T cells (Figure 1B, Figure S3). Upon miR-155 co-transfection, IRES-IL-10 mRNA abundance was slightly increased (Figure 1C), while the expression of IL-10 at protein level was significantly induced (Figure 1D, E), suggesting that miR-155 could translationally activate the engineered IRES-IL-10 mRNA.

Preparation and characterization of ExoIRES-IL-10

The above data showed that intracellular IRES-IL-10 mRNA can be translationally activated by inflammation. To deliver IRES-IL-10 mRNA into the target cells, we chose exosomes as the carrier. Numerous studies used HEK293T cells as donor cells to produce exosomes, as no obvious side-effects were found [24-26]. Thus, the IRES-IL-10 expression plasmids were transfected into the HEK293T cells. The transcribed IRES-IL-10 mRNA was thus passively loaded into the secreted exosomes, with the exosomes designated as ExoIRES-IL-10 (Figure 2A). Compared with the control exosomes ExoNone (derived from untransfected cells) and ExoEmpty (exosomes produced by the cells transfected with empty vector), expression of the exosomal inclusive markers TSG101 and CD9 and exclusive marker GM130 in ExoIRES-IL-10 had no significant changes. Moreover, there was no expression of APOA1 in exosomes, excluding the serum contaminants (Figure 2B). Transmission electron microscopy (TEM) (Figure 2C) and nanoparticle tracer analysis (NTA) (Figure 2D) further confirmed that ExoNone, ExoEmpty and ExoIRES-IL-10 all were similar in morphology and size distribution.

To explore whether exosomes derived from HEK293T cells contain oncogenic or other toxic proteins, exosomes were subjected to mass spectrometry analysis. The results showed that the main proteins in the exosomes are not oncogenic or pro-inflammatory (Table S1). Consistently, treatment
with the exosomes didn’t change the cell viability and proliferation of the recipient cells, though they were efficiently up-taken (Figure S4A-B). Together, our data showed that exosomes derived from HEK-293T had no obvious side-effects, which were consistent with previous studies [24-26].

To test whether transgenic IRES-Il-10 mRNA has been successfully uploaded into exosomes, we used qPCR to analyze the abundance of Il-10 mRNA in the isolated exosomes. As expected, IRES-Il-10 mRNA was robustly encapsulated in ExoIRES-IRES-Il-10, in comparison with the internal control GAPDH (Figure 2E). Frankly, there are no standard housekeeping genes for qPCR analysis of exosomal mRNA. To further confirm the findings, U6 was also used as another control. As expected, similar results were observed, though U6 abundance was much higher than GAPDH (Figure S5A-C). To exclude the artificial effects of qPCR, we carried out the exosome degradation assay. After degradation of the exosomal RNA, Il-10 mRNA was not detectable (Figure 2F). Together, these data confirmed that Il-10 mRNA was efficiently loaded into exosomes.

**ExoIRES-II-10 delivers miR-155 responsive IRES-II-10 mRNA into recipient cells**

In the following experiments, we explored whether the engineered mRNA delivered by ExoIRES-II-10 could be translationally activated by intracellular miR-155. The exosome-treated HEK293T cells were additionally transfected with miR-155 mimics or NC (Figure 3A). qPCR results revealed that miR-155 transfection slightly increased the abundance of IRES-II-10 mRNA in ExoIRES-II-10 treated HEK293T cells (Figure 3B). However, miR-155 transfection greatly enhanced the expression of IL-10 at protein level in ExoIRES-II-10 treated HEK293T cells (Figure 3C, D). We next explored whether endogenous miR-155 in the macrophages could also activate the translation of IRES-II-10 mRNA in macrophages. RAW264.7 cells treated with PBS or LPS/IFN-γ were co-cultured with ExoIRES-II-10 (Figure 3E). Compared with the unpolarized M0, expression of Il-1β, Il-6, Tnf-α and iNos in polarized M1 macrophages increased significantly (Figure S6A), while Il-10 mRNA did not change significantly (Figure S6B). Upon M1 polarization, miR-155 was significantly induced.

![Figure 1. Engineering of inflammation-responsive Il-10 mRNA. (A) Schematic of miR-155-activated IRES-II-10 mRNA. Binding to miR-122, HCV-IRES underwent conformational changes that were conducive to translation. The miR-122 recognition region of the HCV-IRES was replaced with a miR-155 recognition sequence (the substituted bases were red) and downstream ligated to the CDS of mouse Il-10 to achieve miR-155-responsive IL-10 translation activation. (B) Schematic of verifying the function of miR-155-activated IRES-II-10 mRNA at the cellular level by Western blot and qPCR. (C) qPCR analysis of Il-10 mRNA in cells transfected as indicated. GAPDH served as an internal control. (D) Representative Western blot image of IL-10 protein expression in HEK293T cells transfected as indicated. GAPDH served as the loading control. (E) Quantification of Western blot bands by densitometry. Data are presented as mean ± SEM of three independent experiments. * p < 0.05 by one-way ANOVA. NC, negative control. ND, not determined as Ct value greater than 38.](http://www.thno.org)
Accordingly, IL-10 protein in M1 cells receiving ExoIRES-Il-10 treatment was robustly enhanced, comparable to the level of ExoIl-10 treatment (encapsulated with capped Il-10 mRNA without IRES) (Figure 3G-I). These data suggested that ExoIRES-Il-10 efficiently delivered IRES-Il-10 mRNA to target cells and the encapsulated IRES-Il-10 mRNA could be translationally activated by miR-155 in polarized M1 macrophages.

**ExoIRES-Il-10 alleviates local inflammation in ApoE-/- mice**

To explore whether ExoIRES-Il-10 could deliver the cargos to the plaque, distribution of DiR/Dii-labeled exosomes were tracked by *in vivo* imaging system (IVIS) and microscopic analysis of tissue sections. In accordance with previous findings [27], exosomes were found in all the major organs including the liver, spleen, and lungs (Figure 4A-C). Notably, there were abundant exosomes localized in the plaque in the aorta (Figure 4B). Confocal microscopy further confirmed that the co-localization of exosomes in the CD68+ cells (possibly macrophages, macrophage-like smooth muscle cells and some other cell types) in the plaque (Figure 4D). The above data indicated that exosomes entering the plaque could be swallowed by recipient cells in the plaque, and in turn IL-10 protein production was induced if miR-155 were abundantly expressed there. Consistent with the tracing data, two weeks injection of ExoIRES-Il-10 increased the Il-10 mRNA while decreased the expression of Il-1β, Tnf-α and Il-6 in the plaque (Figure 4E, F). The above results proved that ExoIRES-Il-10 could deliver functional IRES-Il-10 mRNA into the plaque for precise control of inflammation.

As shown in Figure 5A, there was no significant difference of IL-10 expression at the protein level between ExoIRES-Il-10 and ExoIl-10 in the plaque. In contrast, the expression of IL-10 in other organs, such as liver, spleen, lung, kidney, and heart, was much higher in ExoIl-10 group (Figure 5B-E, Figure S7). These results demonstrated that ExoIRES-Il-10 would have a relatively specific anti-inflammatory effect in the inflammatory sites of atherosclerosis.

**Therapeutic effects of ExoIRES-Il-10 on atherosclerosis in ApoE-/- mice**

All the above data suggested that ExoIRES-Il-10 might have obvious therapeutic effects on AS while have little toxic effects. ApoE-/- mice fed with high-fat diet for 8 weeks were then injected with indicated exosomes twice a week for 4 weeks (Figure 6A). From...
the gross view of the aorta, ExoIRES-Il-10 and ExoIl-10 treated mice had fewer atherosclerotic plaques than the control mice receiving PBS or ExoNone treatments (Figure 6B, C). Hematoxylin and eosin (H&E) staining and Oil Red O (ORO) staining further showed that ExoIRES-Il-10 and ExoIl-10 treatment decreased the lesion size, while no obvious differences of the therapeutic effects were observed between ExoIRES-Il-10 and ExoIl-10 groups (Figure 6D-F). Moreover, there were no significant differences in lipid levels in serum among all the groups (Figure S8). The above data proved that ExoIRES-Il-10 could achieve on-demand anti-inflammatory effects for atherosclerosis therapy independent of lipid control.

Figure 3. Engineered IRES-Il-10 mRNA in Exosomes is translationally activated by miR-155 in recipient cells. (A) Schematic of exosomes co-cultured with HEK293T cells transfected with miR-155 mimics or NC. (B) qPCR analysis of Il-10 mRNA in HEK293T cells after transfection miR-155 or NC then receiving exosomes as indicated. GAPDH served as an internal control. (C) Western blot analysis of IL-10 protein expression in HEK293T after transfection miR-155 or NC then receiving exosomes as indicated. GAPDH served as the loading control. (D) Quantification of Western blot bands by densitometry. (E) Schematic of exosomes co-cultured with polarized macrophages. (F) qPCR analysis of miR-155 in M0 macrophages and M1 macrophages. (G) qPCR analysis of Il-10 mRNA in polarized macrophages receiving exosomes as indicated. (H) Western blot analysis of IL-10 protein expression in polarized macrophages treated as indicated. GAPDH served as the loading control. (I) Quantification of Western blot bands by densitometry. Data are presented as mean ± SEM of three independent experiments. *, p < 0.05 by student’s t test or one-way ANOVA. ns, no significance. ND, not determined as Ct value greater than 38. NC, negative control.
Consistent with previous studies that HEK293 derived exosomes were safe [25, 26], exosome treatment did not cause any obvious damage in those main organs, as detected by H&E staining (Figure S9). In addition, the liver function biomarkers (alanine transaminase and aspartate aminotransferase), kidney function biomarkers (blood urea nitrogen and creatinine) of mice treated with HEK293T derived exosomes with/without further modification were comparable to PBS-treated group (Figure S10). Echocardiography examination further showed that Exo\(^{\text{RES-Il-10}}\) did not cause obvious damage to cardiac structure (Figure S11). Collectively, these data supported the good safety of Exo\(^{\text{RES-Il-10}}\) in vivo. Notably, we here didn’t find any advantages of Exo\(^{\text{RES-Il-10}}\) in safety vs Exo\(^{\text{Il-10}}\), though the advantages exist theoretically. Beyond the limited sensitivity of the examination method, it is also worth further confirming the advantages of Exo\(^{\text{RES-Il-10}}\) upon long time treatment or under infection challenge.

![Figure 4](http://www.thno.org)  
**Figure 4.** Local inflammation alleviation by Exo\(^{\text{RES-Il-10}}\) in ApoE\(^{-/-}\) mice. (A) Representative IVIS images of mice injected with PBS, 200 \(\mu\)g DiR labeled exosomes via tail vein. IVIS imaging was performed 4 h after injection. (B) Ex vivo fluorescence imaging analysis of the distribution of the DiR-labeled exosomes in different organs, including the aorta, heart, liver, spleen, lung, and kidney. (C) Representative confocal images of the localization of DiI-labeled exosomes in different organs. Mice were injected with 200 \(\mu\)g DiI-labeled exosomes via tail vein and sacrificed 4 h after injection. Scale bar = 50 \(\mu\)m. (D) Representative confocal images showing the localization of DiI-labeled exosomes in CD68\(^+\) cells in the atherosclerotic plaques of aortic roots. Scale bar in panorama, 500 \(\mu\)m. Scale bar in magnified image, 100 \(\mu\)m. (E) Schematic of the experimental procedure. ApoE\(^{-/-}\) mice were fed with a high-fat diet for 8 weeks, followed by the injection of 200 \(\mu\)g Exo\(^{\text{RES-Il-10}}\) or PBS each time, twice a week, for 2 weeks. Then the mice were sacrificed. (F) qPCR analysis of \(\text{Il-10}\) mRNA and inflammation cytokine mRNA levels in lesioned aorta. Data are presented as mean ± SD of three independent experiments. *, \(p < 0.05\) by student’s \(t\) test.
Figure 5. ExoRES-IL-10 precisely induce IL-10 in inflamed tissues in ApoE−/− mice. ELISA measurement of the concentration of IL-10 protein in lesioned aorta (A), liver (B), spleen (C), lung (D), and kidney (E) in ApoE−/− mice. Data are presented as mean ± SD. * p < 0.05 by one-way ANOVA. ns, no significance. n = 5 per group.

Figure 6. Therapeutic effects of ExoRES-IL-10 on atherosclerotic lesions in ApoE−/− mice. (A) Schematic of the experimental procedure. ApoE−/− mice were fed with a high-fat diet for 8 weeks, followed by the injection of 200 µg ExoRES-IL-10, 200 µg ExoIL-10, or PBS each time, twice a week, for 4 weeks. (B) Representative aortic arch view of the atherosclerotic lesions in ApoE−/− mice treated as indicated. AA, ascending aorta; BA, brachiocephalic artery; LCCA, left common carotid artery; LSA, left subclavian artery; DA, descending aorta. (C) Percentage of the atherosclerotic area in the aortic arch treated as above. (D) Representative images of cross-sectional view of the aortic roots stained with H&E, ORO from ApoE−/− mice treated as indicated. Scale bars, 500 µm. (E) Statistical data of the Oil-Red-O (ORO) positive plaque area from D. (F) Representative images of ORO staining of the atherogenic lesion areas in mice treated as above. (G) qPCR analysis of inflammatory cytokine mRNA levels in lesioned aorta. Data are presented as mean ± SD. * p < 0.05 by one-way ANOVA. n = 5 per group.
Discussion

In this study, we first engineered a miR-155-responsive IL-10 mRNA for specific translation induction in inflamed cells. Then, we delivered the engineered II-10 mRNA via exosomes for the treatment of atherosclerosis. In the ApoE-/- mice model, we confirmed that the strategy could efficiently deliver II-10 mRNA into inflamed macrophages in relatively high specificity. Moreover, the encapsulated II-10 mRNA was translationally activated by miR-155, while the translation was rarely induced in other tissues/organs without obvious inflammation. Consistent with the robust II-10 mRNA induction in the plaque, exosome-based delivery of the engineered II-10 mRNA could alleviate the atherosclerosis in ApoE-/- mice.

Anti-inflammatory strategies hold great promise for atherosclerosis treatment. Currently, there are multiple candidates are under clinical trial, such as: (1) inhibition of inflammatory factors or adhesion molecule pathways, such as interleukin-1beta inhibitor Canakinumab[8]; (2) blocker of arachidonic acid biosynthesis, such as lipase A2 inhibitor[9]; (3) interference of inflammatory signal pathway, such as p38MAPK inhibitor Losmapimod[10]. We here proposed that exosome-based delivery of the IRES-II-10 mRNA could alleviate the atherosclerosis in ApoE-/- mice. As atherosclerosis is a chronic disease, long duration of the treatment is needed and strategies with low off-target effects are of great advantage. The advantages of the proposed ExoIRES-II-10 are as follows: (1) The exosomes prevent the encapsulated nucleic acids from degradation by the enzymes in the blood [11, 28]. Moreover, compared with synthetic nanoparticles, exosomes are of great advantage in less immunogenicity [29, 30]. (2) Macrophages are the main inflammatory cells in atherosclerotic plaques [31]. Specifically, the polarization of M1 macrophages aggravates the inflammation response in atherosclerotic plaque [32, 33]. Our study suggests that the exosome-based delivery strategy could target macrophages in a relatively high specificity. (3) In our study, we delivered II-10 mRNA instead of the protein. mRNAs are easier for manipulation than proteins. Moreover, one mRNA could be translated into multiple copies of protein, allowing low need of drug dose. (4) The engineered mRNA could be translationally activated by inflammatory miR-155. Previous studies [23] and our data showed that miR-155 levels were significantly increased in atherosclerotic plaques. After successful delivery, the IRES-II-10 mRNA is translated into IL-10 protein only when miR-155 or other analogues are abundant. In the recipient cells with low expression of miR-155, only tracked IL-10 protein could be induced. All of these make on-demand inflammation alleviation possible.

Development of tissue or stimuli responsive drugs are intensively studied recently, such as light response [34], ultrasound response [35], ROS response [36], pH response [37], which can accurately deliver drugs to the target site in a controlled and safe way, thus avoiding the toxic and side effects. Inspired by the specific translation of HCV RNA due to the HCV-IRES [38], the miR-155-responsive mRNA was developed in the study. miR-155 could activate II-10 mRNA translation via changing the structure of the IRES from translation inhibition to translation activation, allowing ribosome binding to the RNA. Besides, we cannot rule out possibility that miR-155 enhanced the stability of II-10 mRNA. Different from the traditional mechanism that the 2-7 nt from 5' end of miRNA binds the 3' UTR of mRNA, activation of IRES-II-10 mRNA by miR-155 might need a longer matched sequence. In other words, the possibility of non-specific activation by miRNAs with similar core sequence is relatively low. Even if the IRES-II-10 mRNAs were activated by those similar miRNAs, the end results might be also beneficial for the disease control, as miRNAs share the exact same core sequence with miR-155 would have similar pro-inflammatory function as well. Together, the proposed engineering strategy sets an example for manipulating stimuli responsive mRNA, which could be generalized to multiple RNAs and types of diseases. Future refinement of the mRNA, including modification of 5’ -cap, 3’-poly (A) tail, 5’- and 3’-UTRs, codon optimization [22, 39-43], to further improve the specificity and function remain needed.

In the context of atherosclerosis, the host is challenged by low-grade, chronic systemic inflammation. It is thus reasonable to deduce that the slightly elevated miR-155 throughout the body could activate the translation of IRES-II-10 mRNA in a modest way in the organs/tissues beyond the plaque, which could be also beneficial for the disease control. In other words, the system could deliver IL-10 on demand by sensing the level of miR-155 in vivo.

In atherosclerotic plaques, CD68 may not be a specific marker for macrophages, for example, smooth muscle cells (SMCs) that dedifferentiate into macrophage-like cells also express CD68. In addition, we directly performed qPCR and Elisa analysis of the lesioned aortas, which contained a variety of cells besides macrophages. Further analysis with LCM (laser capture microdissection) to isolate specific regions/cells of interest [44], would strengthen our findings. It is interesting to examine whether the SMCs in the plaque had higher expression of miR-155.

http://www.thno.org
and serve as an important target cell for the proposed strategy. As to the manners how exosomes entered the plaques, we preferred the following two possible routes. On one hand, exosomes could circulate into the plaque via the nutrient arteries, especially when angiogenesis is active in the plaque is considered. On the other hand, the vascular endothelium in the lesioned atherosclerotic plaques is incomplete, and the exosomes could also pass through the endothelial barrier to enter the plaque.

Of course, there remains a lot of work to do before clinical translation. Facile isolation and increasing the yield of Exo\textsuperscript{IRES-II-10} remain big challenges. Current isolation methods of exosomes including differential ultracentrifugation, density gradients, precipitation, filtration, size exclusion chromatography, and immune-capture, can only meet the needs of scientific research \cite{45, 46}. Some new separation methods, such as tangential flow filtration (TFF) \cite{47}, have also been reported to improve the separation efficiency. Strategies to selectively enrich the target cargos, such as the RNA binding protein aided enrichment \cite{48}, should be also developed to increase the loading of therapeutics per exosome. It has been also reported that production of exosomes can be boosted by electrical stimulation of donor cells \cite{49}. For quality control of the exosomes, especially establishment of the methods and standards for loading efficiency assessment, are urgently needed. For example, previous studies focused on the small RNA (e.g., miRNA) in the exosomes. However, recently multiple studies have found that functional mRNA could be also encapsulated into exosomes, especially for the overexpressed transgenic RNA \cite{22, 48, 50-52}. However, how to quantify the mRNA copies per exosomes remains a technical challenge. Currently, there are even no good choice of the internal control genes, though GAPDH and \(\beta\)-actin are usually used \cite{22, 48-51, 53}.

In conclusion, the proposed engineered Il-10 mRNA could be translationally responsive to miR-155, allowing relatively low leaky effects in non-inflamed tissues. Exosome-based delivery of the engineered Il-10 mRNA could alleviate the atherosclerosis in ApoE\textsuperscript{-/-} mice while had minimal side-effects, allowing long and systemic application in the future. Generally, our study established a potent platform for tailored inflammation control via exosome-based systemic and repeated delivery of engineered Il-10 mRNA, which could be a promising strategy for atherosclerosis treatment.

**Materials and methods**

**Cell Culture**

HEK293T cells and RAW264.7 cells cultured in DMEM high glucose medium (HyClone, Logan, USA) with 10% fetal bovine serum (FBS), 1% L-glutamine (Gibco, Carlsbad, USA), and 1% penicillin/streptomycin (HyClone, Logan, USA) otherwise indicated. The cell culture was maintained in a humidified incubator with 5% CO\(_2\) at 37 \(^\circ\)C, with the medium changed every 2 days.

**Plasmid Construction**

The designed IRES-II-10 consists of modified HCV-IRES and mouse Il-10 CDS. Briefly, in the designed IRES-II-10, the miR-122 recognition sites in the HCV-IRES were replaced by miR-155 recognition sites and the modified IRES was fused with mouse Il-10 CDS in the 3’ flank. The whole sequence was synthesized in GenScript and subcloned into pWPI with the Pme1 and BstB1 sites. For control, Il-10 CDS without IRES was also cloned into pWPI. The detailed sequences were listed in Table S2.

**Cell Transfection**

HEK293T and RAW264.7 were transfected with control or IRES-II-10 plasmids together with miRNA mimics using HighGene Transfection reagent (ABclonal Technology, Wuhan, China) according to the manufacturer’s protocol. After 6 h of cell transfection, the medium was changed to the complete medium 10% FBS. The detailed sequences of miRNA were listed in Table S3.

**Isolation and Characterization of Exosome**

For the isolation of exosomes, cells were cultured with serum free medium for 48 h before supernatant collection. The cultured medium was then centrifuged at 500 g for 10 min to remove cells and then at 10,000 g for 20 min to eliminate the residual cellular debris, followed by ultracentrifugation at 100,000 g for 2 h. The pellet was washed one time and resuspended in sterile PBS and stored at -80 \(^\circ\)C for the following experiments.

For examination of morphology, purified exosomes were fixed with 2.5% glutaraldehyde and then dropped onto the copper mesh. After staining with 12% phosphotungstic acid aqueous solution (pH = 6.5), the exosomes were visualized using the JEM-1230 electron microscope (JEOL, Tokyo, Japan) and the images were taken by an armed camera. For nanoparticle tracking analysis, purified exosomes from different sources were analyzed by the NanoSight NS300 (Malvern, Egham, UK).

http://www.thno.org
For mRNA loading efficiency analysis, the supernatants were incubated with 10 μg/mL RNase A for 30 min prior to exosomes isolation, as exosomal RNAs are resistant to biochemical degradation by RNase A. To confirm the PCR specificity, the exosomes were lysed and processed with RNase A, followed by reverse transcription qPCR analysis as described below.

**Cellular Uptake of Exosomes in vitro**

RAW264.7 cells cultured in confocal dish were incubated with 40 μg/mL (final concentration) DiI-labeled exosomes for 6 h. Cells were fixed in 4% paraformaldehyde for 10 min at room temperature, followed by three times of PBS wash before further staining. Then the nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen, Waltham, USA). Images were obtained by A1R Spectral Confocal Microscope (Nikon, Tokyo, Japan).

**Translational activation of exosomal IRES-II-10 mRNA in recipient cells**

HEK293T cells were transfected with miR-155 mimics or NC (negative control). Six hours after transfection, the exosomes at the final concentration of 40 μg/mL were added into culture medium, and the expression of II-10 mRNA was detected by qPCR after co-culture for 12 h.

RAW 264.7 cells were stimulated with 200 ng/mL LPS (L2630, Sigma, St. Louis, USA) and 25 ng/mL IFN-γ (315-05, PeproTech, Cranbury, USA) to promote M1 polarization. Twelve hours after polarization, the exosomes at the final concentration of 40 μg/mL were added into culture medium, and the expression of II-10 mRNA was detected by qPCR after co-culture for 12 h. The expression of IL-10 protein was analyzed by Western blot 48 h after co-culture.

**Animal experiments**

All animal experiments were performed under protocols approved by the Animal Care and Use Committee of Fourth Military Medical University. Male ApoE<sup>−/−</sup> mice (7-week-old, 20-22g) were purchased from the Model Animal Research Center of Nanjing University. Mice were maintained under specific pathogen-free conditions with a 12-h light/12-h dark cycle and the temperature kept between 22 °C and 24 °C. After acclimatization for 7 days, mice were fed a high-fat diet (D12492, Research Diet, 45% kcal from fat, 20% kcal from protein, 20% kcal from carbohydrate) for 8 weeks in order to induce atherosclerosis. For treatments, the model mice were then injected with PBS or indicated exosomes (200 μg each time) twice a week via tail vein, for 2 or 4 weeks. At the end of the experiments, the mice were euthanized (200 mg/kg, sodium pentobarbital, i.p.). The aortas of mice were removed under stereo microscope and collected. Blood samples and organs of interest were also isolated and processed for further analysis.

**In vivo and ex vivo Distribution of Exosomes**

To assess the distribution of exosomes in vivo, the purified exosomes were incubated with DiR (Invitrogen, Waltham, USA) at a final concentration of 8 μM at 37 °C for 30 minutes, and the free DiR was removed by another round of centrifugation. Then mice were injected with 200 μg DiR-labeled exosomes (DiR-Exo) via the tail vein. Four hours after injection, the distribution of exosomes in vivo and ex vivo was detected by the IVIS® Lumina II system (PerkinElmer, Waltham, USA) as instructed.

For microscopic analysis of the distribution of exosomes, the exosomes were labeled by Dil (Invitrogen, Waltham, USA) using the method described above before tail vein injection. Four hours after injection, mice were sacrificed and isolated tissues were obtained and mounted in optimum cutting temperature (OCT) compound. Tissue sections were fixed with 4% paraformaldehyde for 10 min and then counterstained with DAPI (Invitrogen, Waltham, USA). In aortas, the internalization of exosomes by CD68<sup>+</sup> cells was analyzed by immunofluorescent staining in frozen sections (ab197519, Abcam). The whole process was kept from light. The fluorescence signals for the labeled exosomes/cells and the nuclei were visualized by A1R Spectral Confocal Microscope (Nikon, Tokyo, Japan).

**Cell viability assay**

RAW264.7 cells were cultured in 6-well plates, then different groups of exosomes (final concentration is 40 μg/mL) or PBS were added to per well. About 24 h after treatments, the cell viability was detected by CCK8 assay as instructed.

**Western blot**

Exosomes, or cells were harvested and subjected to cell lysis buffer (Beyotime Biotechnology, China) supplemented with protease inhibitor cocktail (Roche, Basel, Switzerland) at 4 °C for 30 min. The protein content was determined using a BCA protein assay kit (Thermo Fisher Scientific, Waltham, USA). Equal amounts of proteins were then concentrated on 6% SDS-PAGE and separated by 12% SDS-PAGE (120 V for stacking gel and 160 V for separation gel), followed by transferring to nitrocellulose filter membranes with the ice bath. The membranes were blocked with 5% bovine serum albumin (BSA) in TBS-T (tris buffered saline-Tween 20) for 1 h at room...
temperature and then incubated with primary antibodies overnight at 4 °C. Antibodies used were anti-IL-10 (sc-32815, Santa Cruz), anti-GM130 (11308-1-AP, Proteintech), anti-TSG101 (ab83, Abcam), anti-CD9 (AF5139, Affinity Biosciences), anti-APOA1 (14427-1-AP, Proteintech), anti-GAPDH (60004-1-Ig, Proteintech). After washing three times in TBS-T, the membranes were incubated with anti-rabbit (7074, CST) or anti-mouse (7076, CST) horseradish peroxidase-conjugated secondary antibodies corresponding to the primary antibodies at room temperature for 1h and then visualized using the Amersham™ enhanced chemiluminescence (ECL) Prime western blotting detection reagents (Cytiva, Little Chalfont, UK). Western blot band intensity was quantified by Image J.

**qPCR Analysis**

The lesioned aortas and other tissues of interest were processed with TRIzol® reagent (Invitrogen, Waltham, USA) according to the manufacturer’s instructions. miRNA and mRNA were extracted and reversely transcribed to cDNA by miRcute Plus miRNA First-Strand cDNA Kit (TIANGEN, Beijing, China) and First Strand cDNA synthesis kit (Genenode, Beijing, China), respectively, following the manufacturer’s protocol. qPCR reactions were performed by FastStart Essential DNA Green Master (Roche, Basel, Switzerland). All PCR reactions were run at least in triplicate, and target RNA expression was normalized to U6 or GAPDH levels. Relative expression was calculated by normalizing to the control samples using the 2^\(-\Delta\Delta C_t\) method otherwise indicated. The sequences of PCR primers are provided in Table S4.

**Serum biochemistry**

Blood samples were collected after fasting for 8 h. The whole blood samples were kept at room temperature for 2 h or overnight at 4 °C and centrifuged at 4 °C for 4,000 g for 15 min, then the supernatants were stored at -20 °C for detection. Blood lipid level, liver function and renal function parameters were measured by Chemray 800 and Chemray 240 Chemistry analyzer and reagents (Rayto, Shenzhen, China) at Wuhan Servicebio technology CO, LTD.

**Enzyme-linked immunosorbent assays**

The aorta and other organs of mice were removed under stereo microscope, and then the lesioned aortas were isolated. The isolated tissues were collected, weighed, and lysed immediately for analysis of IL-10 protein concentrations with the commercial ELISA kit (Proteintech, Wuhan, China). The assay was performed according to the manufacturer’s instruction and the relative concentrations were calculated per tissue weight.

**Histology**

Tissues, including the aorta, heart, liver, spleen, lung, and kidney, with the surrounding adipose tissue removed, were fixed at 4% paraformaldehyde for 1 h and then the specimens were transferred to PBS containing 30% sucrose overnight. The specimens were embedded in OCT compound and sectioned. Hematoxylin-eosin (H&E) and ORO staining were performed according to the routine protocol. The size of lesions and the area of lipid core were calculated by ImageJ. The histological changes were analyzed from the H&E staining of the main organs by two independent specialists.

**Protein profiling of exosomes by mass spectrometry**

Exosomes isolated were subjected to BangFei Bioscience (Beijing, China) for mass spectrometry and subsequent bioinformatics analyses. Each group contained 3 samples. Briefly, total protein of ExoNone and ExoIRES-IL-10 were extracted with RIPA lysis buffer and electrophoresis was done to grossly assess protein quality. Then, sample proteins were digested by trypsin and separated by high-performance liquid chromatography (Easy nLC/Ultimate 3000, Thermo Scientific, USA), followed by mass spectrometry analysis (Orbitrap Fusion Lumos, Thermo Scientific, USA). Data were processed using MaxQuant software (version 2.0.1), with peptide false discovery rate (FDR) ≤ 0.01 and protein FDR ≤ 0.01.

**Echocardiography**

Mouse hairs from chest to abdomen were first removed using a chemical hair remover. Then the mice were anesthetized with isoflurane (2% induction, 1.2% maintenance) and placed on a temperature-controlled heating pad for normal body temperature maintenance. Animal echocardiography was performed by experienced technicians using Vevo 2100 Imaging System (FUJIFILM VisualSonics, Canada). The heart rate was kept between 400-500 beats per minute during the examination. Two-dimensional short-axis M-mode echocardiography was conducted at the level of the mid-papillary muscle. Parasternal long axis view (PLAX), short axis view and four-chamber view were scanned for multiple cardiac functional parameters. All evaluation parameters were averaged from five cardiac cycles. Investigators were blinded to the identity of animals.
Statistical Analysis
Data are expressed as mean ± SEM or mean ± SD. Shapiro–Wilk test was used to determine data distribution normality. Student’s t-test was used for two group comparison, and one-way analysis of variance (ANOVA) with Tukey’s posthoc test was used for comparison among 3 or more groups (Graphpad Prism 8.0). P values of < 0.05 indicate statistical significance.

Supplementary Material
Supplementary figures and tables. http://www.thno.org/v11p9988s1.pdf

Acknowledgements
This study was funded by NSFC 81871357 and 81671690 to Yuan LJ, NSFC 31771507 and 81970737 to Yang GD, Provincial Scientific Foundation of Shaan’xi (2020TD-038) and Fund of Tangdu Hospital (2021LCY(006) to Yuan LJ.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999; 340: 115-26.
2. Kobiyama K, Ley K. Atherosclerosis. Circ Res. 2018; 123: 1118-20.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-95.
4. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 AHA/ACC guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019; 74: e177-e222.
5. Grundy SM, Stone NJ, Bailey AL, Beam C, Bircher KK, Blumenthal RS, et al. 2018 AHA/ACC/ACCF/AACVPR/AAPA/ABC/AGS/APHH/AHA/ASPNC/LA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019; 139: e1182-e143.
6. Collet JP, Thiele H, Barbaro E, Barthelemy O, Bauriedl J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42: 1289-367.
7. Weber C, van Hundelhausen P. CANTOS trial validates thi ferritinopathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting. Circ Res. 2017; 121: 1191-21.
8. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with Canakinumab for cardiovascular disease. N Engl J Med. 2017; 377: 1119-31.
9. Rosenson RS, Hislop C, Elliott M, Stasis Y, Goulter M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol. 2010; 56: 1079-88.
10. Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet. 2014; 384: 1187-95.
11. Kalluri R, LeBlue VS. The biology, function, and biomedical applications of exosomes. Science. 2020; 367.
12. Liu C, Su C. Design strategies and application progress of therapeutic exosomes. Theranostics. 2019; 9: 1015-28.
13. Kamermark S, LeBlue VS, Sugimoto H, Yang S, Ruizov CF, Melo SA, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017; 546: 498-503.
14. Zhou X, Li Z, Qi M, Zhao P, Duan Y, Yang G, et al. Brown adipose tissue-derived exosomes mitigate the metabolic syndrome in high fat diet mice. Theranostics. 2020; 10: 8197-210.
15. Pinderski Olsland L, Hejde C, Oliveira T, Hagenbaugh A, Territo M, Bernter J, et al. Interleukin-10 blocks atherosclerotic events in vivo and in vitro. Arterioscler Thromb Vasc Biol. 1999; 19: 2847-53.
16. Moore KW, de Waal Malerley R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2003; 19: 683-765.
17. Liu Y, Li D, Chen J, Xie J, Bandypadyay S, Zhang D, et al. Inhibition of atherosclerosis in LDLR knockout mice by systemic delivery of adenosine-associated virus type 2-hil-10. Atherosclerosis. 2006; 188: 19-27.
18. Kamaly N, Fredman G, Fojas J, Subramanian M, Choi WL, Zepeda K, et al. Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano. 2016; 10: 5280-92.
19. Schult P, Roth H, Adams RL, Mac C, Imbert L, Orbik C, et al. microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. Nat Commun. 2018; 9: 2613.
20. Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak J, et al. Hepatitis C virus infection in cancer cells is detectable by ultrasmall micelles. Cell. 2015; 160: 1099-110.
21. Sun W, Xing C, Zhao L, Zhao P, Yang G, Yuan L. Ultrasound assisted exosomal delivery of tissue responsive mRNA for enhanced efficacy and minimized off-target effects. Mol Ther Nucleic Acids. 2020; 20: 558-67.
22. Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, et al. Non-invasive targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017; 546: 498-503.
23. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in endogenous GSH and enhanced onodynamic cancer therapy. Adv Mater. 2020; 31: e1900730.
24. Kim H, Kim Y, Miraazgha I, Heo J, Kim YN, Shin JH, et al. Exosome-based delivery of super-repressor BkapPalpha relieves sepsis-associated organ damage and mortality. Sci Adv. 2020; 6: eaaaz980.
25. Wicklander OP, Nordin JZ, O’Loughlin A, Gustafsson Y, Corso G, Magr I, et al. Extracellular vesicles in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015; 4: 26316.
26. O’Brien K, Brynek N, Lippetto S, Lauren TC, Breaker XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020; 21: 585-606.
27. Eshkarsky OM, Nordin JZ, Hagey DW, de Jong OG, Schifferers RM, Andaloussi SE, et al. Extracellular vesicles as drug delivery systems: Why and how? Adv Drug Deliv Rev. 2020; 159: 332-43.
28. O’Brien K, Brynek N, Lippetto S, Lauren TC, Breaker XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020; 21: 585-606.
29. Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schifferers RM, Andaloussi SE, et al. Extracellular vesicles as drug delivery systems: Why and how? Adv Drug Deliv Rev. 2020; 159: 332-43.
30. Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019; 25: 115-98.
31. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011; 145: 341-55.
32. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement T, et al. Regulation of macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016; 118: 653-67.
33. Andaloussi SE, et al. Extracellular vesicles as drug delivery systems: Why and how? Adv Drug Deliv Rev. 2020; 159: 332-43.
34. Koelwyn GJ, Corr EM, Erbay E, Moore KJ. Regulation of macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016; 118: 653-67.
35. Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schifferers RM, Andaloussi SE, et al. Extracellular vesicles as drug delivery systems: Why and how? Adv Drug Deliv Rev. 2020; 159: 332-43.
45. Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andrianontsehaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 7: 1535750.

46. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006; Chapter 3: Unit 3 22.

47. Watson DC, Yung BC, Bergamaschi C, Chowdhury B, Bear J, Stellas D, et al. Scalable, cGMP-compatible purification of extracellular vesicles carrying bioactive human heterodimeric IL-15/lactadherin complexes. J Extracell Vesicles. 2018; 7: 1442088.

48. Li Z, Zhou X, Wei M, Gao X, Zhao L, Shi R, et al. In vitro and in vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated with miRNA or CRISPR/dCas9. Nano Lett. 2019; 19: 16-28.

49. Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng. 2020; 4: 69-83.

50. Li Z, Zhao P, Zhang Y, Wang J, Wang C, Liu Y, et al. Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model. Theranostics. 2021; 11: 2953-65.

51. Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, et al. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther. 2013; 21: 101-8.

52. Kojima R, Bojar D, Rizzi G, Hamri GC, El-Baba MD, Saxena P, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nat Commun. 2018; 9: 1305.

53. Usman WM, Pham TC, Kwok YY, Vu LT, Ma V, Peng B, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018; 9: 2359.